Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Matthew H. Kulke
Dana-Farber Cancer Institute

Dieter Hörsch
Zentralklinik Bad Berka, Germany

Martyn E. Caplin
Royal Free Hospital, UK

Lowell B. Anthony
University of Kentucky, lowell.anthony@uky.edu

Emily Bergsland
University of California - San Francisco

See next page for additional authors

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub

Part of the Oncology Commons

Repository Citation
Kulke, Matthew H.; Hörsch, Dieter; Caplin, Martyn E.; Anthony, Lowell B.; Bergsland, Emily; Öberg, Kjell; Welin, Staffan; Warner, Richard R. P.; Lombard-Bohas, Catherine; Kuna, Pamela L.; Grande, Enrique; Valle, Juan W.; Fleming, Douglas; Lapuerta, Pablo; Banks, Phillip; Jackson, Shanna; Zambrowicz, Brian; Sands, Arthur T.; and Pavel, Marianne, "Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome" (2017). Internal Medicine Faculty Publications. 134.
https://uknowledge.uky.edu/internalmedicine_facpub/134

This Article is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Authors

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Notes/Citation Information

© 2016 by American Society of Clinical Oncology

The copyright holder has granted the permission for posting the article here.

Digital Object Identifier (DOI)
https://doi.org/10.1200/JCO.2016.69.2780

This article is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/134
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome


ABSTRACT

Purpose
Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting.

Patients and Methods
Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat ethyl 500 mg.

Results
Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were −0.81 for telotristat ethyl 250 mg (P < .001) and −0.69 for telotristat ethyl 500 mg (P < .001). At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg were −0.9, −1.7, and −2.1, respectively. Responses, predefined as a BM frequency reduction ≥ 30% from baseline for ≥ 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg, respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindoleacetic acid versus placebo at week 12 (P < .001). Mild nausea and asymptomatic increases in gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment.

Conclusion
Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary 5-hydroxyindole acetic acid.

J Clin Oncol 35:14-23. © 2016 by American Society of Clinical Oncology

INTRODUCTION

Patients with advanced neuroendocrine tumors (NETs) may develop carcinoid syndrome, a condition associated with tumoral secretion of serotonin and characterized by diarrhea, flushing, bronchial constriction, and the development of cardiac valvular fibrosis, which may lead to heart failure.1-3 Diarrhea, one of the most prominent symptoms of carcinoid syndrome, negatively affects patients’ emotional well-being and social and physical functioning.4 Serotonin is metabolized into 5-hydroxyindoleacetic acid (5-HIAA), a biomarker measurable in the urine and often used to follow treatment response in patients with carcinoid syndrome.4,5 High systemic serotonin levels, as reflected by elevated urinary 5-HIAA (u5-HIAA), most often in the setting of widespread tumor metastases, are associated with severe carcinoid syndrome, carcinoid heart disease, and poor prognosis.1,2,4,6,7

Somatostatin analogs (SSAs), the standard treatment for patients with carcinoid syndrome, are an effective initial treatment, but patients may develop recurrent symptoms during the course of
their disease.8-10 Tryptophan hydroxylase (TPH), the rate-limiting enzyme in serotonin synthesis, converts tryptophan to 5-
hydroxytryptophan, which is subsequently converted to serotonin.3 The hypothesis that inhibiting TPH may reduce symptoms of car-
cinoid syndrome was tested in 1967 by Engelman et al9 with par-
achlorophenylalanine. In that study, symptoms improved and u5-
HIAA levels were reduced. However, parachlorophenylalanine crossed the blood-brain barrier, causing severe CNS-related adverse effects, including depression.

Telotristat ethyl is a novel, oral, small-molecule TPH inhibitor that has a high molecular weight and acidic moieties, which inhibit it from crossing the blood-brain barrier.5,10 Two early studies in patients with carcinoid syndrome suggested that telotristat etiprate, the hippurate salt of telotristat ethyl, reduced bowel movement (BM) frequency and decreased u5-HIAA without overt CNS adverse effects.11,12 Although the name “telotristat etiprate” was previously granted by the United States Adopted Names Council and has been used in the literature,11,12 recent guidance from the US Food and Drug Administration recommends using the name of the neutral form rather than the name of the salt for drug products. Therefore, telotristat ethyl is used herein. In this international, multicenter, randomized, double-blind, placebo-controlled phase III trial (TELESTAR), we assessed the safety and efficacy of telo-
tristat ethyl in patients with carcinoid syndrome not adequately controlled with SSA therapy.

Efficacy and Safety Assessments

All primary and secondary efficacy assessments, except u5-HIAA, were self-reported in daily electronic diaries. The primary end point of the study was mean reduction from baseline in daily BMs averaged over 12 weeks. Key secondary end points included change from baseline in u5-
HIAA at week 12, the number of daily flushing episodes, and abdominal pain severity (on a scale of 0 to 10) averaged over 12 weeks. Responders were preselected as patients experiencing a ≥30% reduction in BM frequency (relative to baseline) for ≥50% of the DBT period. Additional efficacy end points included change from baseline in the European Or-
ganisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) scores, rescue short-acting SSA use, stool consistency, and the proportion of days with urgency to defeate (Data Supplement). Patient use of over-the-counter antidiarrheals was not tracked in this study.

Adverse events (AEs) were graded as mild, moderate, or severe (Data Supplement). Depression-related AEs were events of special interest, and a validated two-question case-finding instrument was administered to all patients at each study visit.15 A pharmacokinetic analysis sub-study was performed in 40 patients (Data Supplement). The planned efficacy analyses were based on the intent-to-treat population. However, a single patient initially randomly assigned to receive telotristat ethyl 500 mg was sub-
sequently deemed a screen failure and was not treated. This same patient was subsequently re-evaluated, found to meet all eligibility criteria, random-
ly assigned a second time to telotristat ethyl 250 mg, and included in the telotristat ethyl 250 mg group for analysis of efficacy and safety. The safety population consisted of all patients who received at least one dose of the study drug.

Statistical Analysis

A blocked Wilcoxon rank sum statistic (stratified by baseline u5-HIAA levels) was used to evaluate the primary efficacy end point. The non-
parametric Hodges-Lehmann estimator was used to describe the magnitude of the treatment effect. Parallel analyses were used for additional efficacy end points, including change from baseline in u5-HIAA level, number of flushing episodes, abdominal pain severity, EORTC QLQ-C30 scores, stool consis-
tency, and the proportion of days with urgency to defeate. A Bonferroni-
based multiple comparison procedure with restrictions on the order of testing treatment group hypotheses was applied to control the local and overall type I error probabilities (α = .05) for the primary and secondary efficacy end points. A more detailed description of the statistical methods used in this study is provided in the Data Supplement.

Patient Disposition

In this study (N = 135), 45 patients received treatment in each study arm. A total of 136 random assignments occurred; one
Enrollment

- Randomly allocated 1:1:1 (n = 135; 136 random allocations*)

Allocations (DBT)

- Allocated to telotristat ethyl 250 mg three times per day
  - Received allocated intervention (n = 45)
  - Did not receive allocated intervention (n = 0)
- Allocated to telotristat ethyl 500 mg three times per day
  - Received allocated intervention (n = 46*)
  - Did not receive allocated intervention* (n = 0)
- Allocated to placebo
  - Received allocated intervention (n = 45)
  - Did not receive allocated intervention (n = 0)

Follow-up

- Lost to follow-up (n = 0)
- Discontinued intervention in DBT period (n = 7)
  - Adverse event† (n = 3)
  - Death‡ (n = 2)
  - Physician decision (n = 1)
  - Withdrawal of consent (n = 1)
  - Other (n = 0)
- Lost to follow-up (n = 0)
- Discontinued intervention in DBT period (n = 4)
  - Adverse event† (n = 2)
  - Death‡ (n = 0)
  - Physician decision (n = 0)
  - Withdrawal of consent (n = 1)
  - Other (n = 1)
- Lost to follow-up (n = 0)
- Discontinued intervention in DBT period (n = 8)
  - Adverse event† (n = 2)
  - Death‡ (n = 1)
  - Physician decision (n = 1)
  - Withdrawal of consent (n = 3)
  - Other (n = 1)

Analysis

- Analyzed (n = 45)
  - Excluded from analysis (n = 0)
- Analyzed (n = 45)
  - Excluded from analysis (n = 0)
- Analyzed (n = 45)
  - Excluded from analysis (n = 0)

Allocations (OLE)§

- Completed the DBT (n = 38)
  - Entered the OLE (n = 38)
- Completed the DBT (n = 41)
  - Entered the OLE (n = 39)
- Completed the DBT (n = 38)
  - Entered the OLE (n = 38)

All patients treated with telotristat ethyl 500 mg

- Lost to follow-up (n = 0)
- Discontinued intervention in the OLE
  - Adverse event (n = 9)
  - Death (n = 4)
  - Lack of efficacy (n = 5)
  - Physician decision (n = 2)
  - Withdrawal of consent (n = 7)
  - Other (n = 3)

Excluded

- (n = 39)
- Not meeting inclusion/exclusion criteria (n = 32)
- Declined to participate or withdrew consent (n = 3)
- Death (n = 2)
- Other reasons (n = 2)

Fig 1. CONSORT diagram. Patient flow in the double-blind treatment (DBT) period of the TELESTAR study. (*) One patient initially randomly assigned to receive telotristat ethyl 500 mg was designated a screen failure because of bruising found during physical examination. This patient was subsequently rescreened, met all eligibility criteria, and was subsequently randomly assigned a second time to telotristat ethyl 250 mg. This patient was included in the telotristat ethyl 250 mg group for both efficacy and safety analyses. (†) Additional adverse events leading to study discontinuation are fully described in Table 3. (‡) A total of five deaths occurred after random assignment, but two patients (one each receiving placebo and telotristat ethyl 250 mg three times per day) previously withdrew from the study because of adverse events. (§) Patient flow into the open-label extension (OLE) reflects data extracted from the interim clinical study report.
Telotristat Ethyl for the Treatment of Carcinoid Syndrome

Table 1. Demographic and Baseline Characteristics of the Patient Population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo (n = 45)</th>
<th>Telotristat Ethyl (three times per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td></td>
<td>250 mg (n = 45)</td>
<td>500 mg (n = 45)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>63.3 (8.7)</td>
<td>62.4 (9.1)</td>
</tr>
<tr>
<td></td>
<td>64.9 (9.0)</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>24 (53.3)</td>
<td>21 (46.7)</td>
</tr>
<tr>
<td></td>
<td>25 (55.6)</td>
<td></td>
</tr>
<tr>
<td>Daily BM frequency</td>
<td>5.2 (1.4)</td>
<td>6.1 (2.1)</td>
</tr>
<tr>
<td></td>
<td>5.8 (2.0)</td>
<td></td>
</tr>
<tr>
<td>Minimum, maximum</td>
<td>3.5-9.0</td>
<td>3.5-13.0</td>
</tr>
<tr>
<td></td>
<td>3.6-12.5</td>
<td></td>
</tr>
<tr>
<td>SSA therapy at study entry*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ooctreotide LAR</td>
<td>30 (66.7)</td>
<td>40 (88.9)</td>
</tr>
<tr>
<td>Lanreotide depot</td>
<td>15 (33.3)</td>
<td>5 (11.1)</td>
</tr>
<tr>
<td></td>
<td>12 (26.7)</td>
<td></td>
</tr>
<tr>
<td>SSA use above labeled dose†</td>
<td>18 (40.0)</td>
<td>19 (42.2)</td>
</tr>
<tr>
<td></td>
<td>21 (46.7)</td>
<td></td>
</tr>
<tr>
<td>u5-HIAA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ ULN (0-15 mg/24 hours)</td>
<td>12 (26.7)</td>
<td>12 (26.7)</td>
</tr>
<tr>
<td>&gt; ULN (&gt;15 mg/24 hours)</td>
<td>26 (57.8)</td>
<td>26 (57.8)</td>
</tr>
<tr>
<td>Unknown</td>
<td>7 (15.6)</td>
<td>7 (15.6)</td>
</tr>
<tr>
<td>Baseline values, mg/24 hours</td>
<td>81.0 (n = 44)</td>
<td>92.6 (n = 42)</td>
</tr>
<tr>
<td>CgA at baseline, µg/L</td>
<td>885.7 (n = 42)</td>
<td>503.2 (n = 43)</td>
</tr>
<tr>
<td>Cutaneous flushing episodes per day</td>
<td>1.8 (1.9)</td>
<td>2.8 (3.7)</td>
</tr>
<tr>
<td>Total No. of patients with ≥ 2 episodes per day</td>
<td>2.7 (3.4)</td>
<td>52 (38.5)</td>
</tr>
<tr>
<td>Abdominal pain score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 3 of 10</td>
<td>2.5 (2.3)</td>
<td>2.6 (2.3)</td>
</tr>
<tr>
<td>No. of patients with severe abdominal pain, score of ≥ 3 of 10</td>
<td>2.6 (2.2)</td>
<td>17 (37.8)</td>
</tr>
<tr>
<td></td>
<td>2.6 (40.0)</td>
<td></td>
</tr>
<tr>
<td>CgA at baseline, µg/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>u5-HIAA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ ULN (0-15 mg/24 hours)</td>
<td>12 (26.7)</td>
<td>12 (26.7)</td>
</tr>
<tr>
<td>&gt; ULN (&gt;15 mg/24 hours)</td>
<td>26 (57.8)</td>
<td>26 (57.8)</td>
</tr>
<tr>
<td>Unknown</td>
<td>7 (15.6)</td>
<td>7 (15.6)</td>
</tr>
<tr>
<td>Baseline values, mg/24 hours</td>
<td>81.0 (n = 44)</td>
<td>92.6 (n = 42)</td>
</tr>
<tr>
<td>CgA at baseline, µg/L</td>
<td>885.7 (n = 42)</td>
<td>503.2 (n = 43)</td>
</tr>
<tr>
<td>Cutaneous flushing episodes per day</td>
<td>1.8 (1.9)</td>
<td>2.8 (3.7)</td>
</tr>
<tr>
<td>Total No. of patients with ≥ 2 episodes per day</td>
<td>2.7 (3.4)</td>
<td>52 (38.5)</td>
</tr>
<tr>
<td>Abdominal pain score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 3 of 10</td>
<td>2.5 (2.3)</td>
<td>2.6 (2.3)</td>
</tr>
<tr>
<td>No. of patients with severe abdominal pain, score of ≥ 3 of 10</td>
<td>2.6 (2.2)</td>
<td>17 (37.8)</td>
</tr>
<tr>
<td></td>
<td>2.6 (40.0)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BM, bowel movement; CgA, chromogranin-A; LAR, long-acting release; SD, standard deviation; SSA, somatostatin analog; u5-HIAA, urinary 5-hydroxyindoleacetic acid; ULN, upper limit of normal.

*At study entry, patients received a minimum SSA dose of octreotide LAR 30 mg or lanreotide depot 120 mg once every 4 weeks or the highest tolerated dose. Includes patients who received SSA therapy via a subcutaneous continuous infusion pump.

†Above-label dosing was defined as a cumulative dose of > 30 mg octreotide LAR or > 120 mg lanreotide over the course of 4 weeks.8,16

Efficacy

BM frequency. Treatment with telotristat ethyl at either dosage was associated with statistically significant reductions in BM frequency over time compared with placebo (Fig 2A). The Hodges-Lehmann estimator for patients receiving telotristat ethyl 250 mg was −0.81 and −0.69 for those receiving telotristat ethyl 500 mg (P < .001). The arithmetic mean reduction in daily BM frequency from baseline to week 12 was −1.7 and −2.1 with the telotristat ethyl 250 mg and 500 mg, respectively, and −0.9 for the placebo (Fig 2B). Individual patient responses during the DBT period are shown in Figures 2C and 2D. In total, 44% and 42% of participants who received telotristat ethyl 250 mg and 500 mg, respectively, were classified as BM responders versus 20% of patients who received the placebo. The odds ratios (ORs) were 3.49 (95% CI, 1.33 to 9.16) and 3.11 (95% CI, 1.20 to 8.10) for telotristat ethyl 250 mg and 500 mg, respectively (Table 2). In the OLE, BM reductions were consistent with results from the DBT period (Fig 2A).

u5-HIAA. In patients who were evaluable at baseline and week 12, treatment with telotristat ethyl at either dosage was associated with statistically significant reductions in u5-HIAA levels compared with placebo. The Hodges-Lehmann estimator was −30.1 mg/24 hours and −33.8 mg/24 hours for telotristat ethyl 250 mg and 500 mg, respectively (P < .001 for both). At week 12, arithmetic mean u5-HIAA levels decreased by 40.1 mg/24 hours and by 57.7 mg/24 hours in the telotristat ethyl 250 mg and 500 mg groups, respectively. The mean u5-HIAA levels increased in the placebo group by 11.5 mg/24 hours at week 12. Individual patient responses during the DBT period are shown in Figures 3A and 3B. In a post hoc analysis of patients treated with telotristat ethyl, 78% (n = 25) and 87% (n = 26) of patients in the 250 mg and 500 mg groups, respectively, experienced a ≥30% decrease in u5-HIAA levels compared with 10% (n = 3) in the placebo group.

Flushing and abdominal pain. Relatively few patients reported two or more flushing episodes per day or abdominal pain (rating of ≥3 of 10 in severity) at baseline (Table 1), and changes in these end points did not reach statistical significance (Appendix Table A1).

Quality of life and other end points. EORTC QLQ-C30 diarrheasubscale scores, which were averaged over the DBT period, improved by 19.2 points (on a scale of 0 to 100) and by 21.6 points in the telotristat ethyl 250 mg and 500 mg groups, respectively, and by only 8.5 points in the placebo group (P = .039 and P = .051 for...
telotristat ethyl 250 mg and 500 mg, respectively.). No significant treatment group differences were observed in the nausea and vomiting subscale. No overall differences in the global health status subscale were observed between treatment arms, although patients classified as BM responders reported modest improvements in overall quality of life compared with nonresponders in all three treatment arms (AppendixTable A2). Some evidence that telotristat ethyl may also improve stool consistency, reduce the urgency to defecate, and reduce rescue short-acting octreotide use was observed (AppendixTable A1; AppendixFig A1). Pharmacokinetic models also support a dose response to treatment of both u5-HIAA and BM frequency (Data Supplement).

**Safety**

The overall incidence of treatment-emergent adverse events (TEAEs) across the three treatment arms was similar (Table 3; Appendix Table A3). A higher incidence of nausea was noted in patients in the telotristat ethyl 500 mg group (31.1%) compared with patients in the telotristat ethyl 250 mg group or the placebo group (13.3% and 11.1%, respectively). One patient receiving placebo discontinued the study drug because of nausea; however, no patients receiving telotristat ethyl discontinued because of nausea. Dose-related increases in hepatic enzymes, particularly gamma-glutamyl transferase, were observed in both telotristat ethyl groups (Table 3). In the DBT period, depression-related AEs, including depression, depressed mood, and decreased interest, occurred during treatment in 6.7%, 6.7%, and 15.6% of patients in the placebo, telotristat ethyl 250 mg, and 500 mg groups, respectively. However, no patient reporting depression required initiation of new antidepressant therapy, and no cases of depression resulted in treatment discontinuation. In the OLE, among patients who crossed over from placebo to telotristat ethyl 500 mg, there was only one new report of decreased interest, but no new reports of depression or depressed mood were made between weeks 12 and 24 (Appendix Table A4).

**DISCUSSION**

In this randomized, double-blind, placebo-controlled phase III study in patients with carcinoid syndrome not adequately
Table 2. Efficacy Assessments in the DBT Period

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo (n = 45)</th>
<th>Telotristat Ethyl (three times per day)</th>
<th>Placebo (n = 45)</th>
<th>Telotristat Ethyl (three times per day)</th>
<th>Placebo (n = 45)</th>
<th>Telotristat Ethyl (three times per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%) Mean (SD) OR</td>
<td></td>
<td>No. (%) Mean (SD) OR</td>
<td></td>
<td>No. (%) Mean (SD) OR</td>
<td></td>
</tr>
<tr>
<td>BM frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daily reduction averaged over 12 weeks</td>
<td>−0.62 (0.83)</td>
<td>−1.43 (1.36)</td>
<td>−1.46 (1.31)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arithmetic mean treatment difference</td>
<td>—</td>
<td>−0.81</td>
<td>−0.83</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodges-Lehmann estimator*</td>
<td>—</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Responder analysis†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline in BM frequency at week 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BM responder†</td>
<td>9 (20)</td>
<td>20 (44)</td>
<td>.011</td>
<td>3.49</td>
<td>1.33 to 9.16</td>
<td>.020</td>
</tr>
<tr>
<td>BM nonresponders</td>
<td>26</td>
<td>20 (10.1)</td>
<td>16</td>
<td>−2.6 (1.6)</td>
<td>16</td>
<td>−3.1 (2.1)</td>
</tr>
<tr>
<td>u5-HIAA†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absolute change from baseline levels at week 12, mg/24 h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arithemetic mean treatment difference</td>
<td>—</td>
<td>−51.6</td>
<td>−69.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodges-Lehmann estimator*</td>
<td>—</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BM, bowel movement; CL, confidence limit; DBT, double-blind treatment; OR, odds ratio; SD, standard deviation; u5-HIAA, urinary 5-hydroxyindoleacetic acid.

*Nonparametric measure derived as the median of all possible differences between the groups.
†Responders were defined as having ≥ 30% reduction in BM frequency for ≥ 50% of study period.
‡Data include only patients for whom both baseline and week 12 assessments were available.
controlled on SSA therapy, treatment with the oral TPH inhibitor telotristat ethyl was associated with statistically significant reductions in BM frequency compared with placebo. Marked decreases in u5-HIAA were also associated with treatment. Although the overall incidence of TEAEs was similar across all treatment groups, nausea and elevated gamma-glutamyl transferase were reported more often in patients receiving telotristat ethyl. In patients receiving subsequent treatment in the OLE, reductions in BM frequency seemed to be sustained, and no new safety signals were observed. To our knowledge, this study represents one of the largest randomized placebo-controlled studies conducted to date to assess symptom control in patients with carcinoid syndrome.

SSAs, including octreotide and lanreotide, are widely used for the treatment of carcinoid syndrome, but not all patients achieve complete symptom control.4,7,18 Moreover, patients with carcinoid syndrome often live for years and may develop recurrent symptoms.4,6 There are few other treatment options, and the development of new treatments for carcinoid syndrome has proved challenging, in part because of the rarity of the condition and the lack of new drug candidates.19-21

BM frequency is a useful end point in carcinoid syndrome studies because of its impact on patient function and well-being. A decrease of approximately three BMs per day (from a baseline of five to six BMs per day) was reported with octreotide LAR in patients with carcinoid syndrome.17 In this study, in patients experiencing diarrhea despite concomitant SSA therapy, BM frequency decreased by approximately two BMs per day with telotristat ethyl.

We performed a prespecified responder analysis, defining responders as patients experiencing ≥ 30% decrease in BM frequency for ≥ 50% of the DBT period, thereby measuring both magnitude and duration of response.10,11 More than 40% of patients treated with telotristat ethyl were responders versus 20% of patients treated with placebo. Consistent with these observations, we also observed improvements in quality of life using the EORTC QLQ-C30 diarrhea subscale. No differences in the EORTC QLQ-C30 global health scores were observed. In fact, these scores were similar across all three treatment arms, suggesting that no quality of life detriment was associated with treatment. Interestingly, only minimal changes in overall EORTC QLQ-C30 global health scores were observed in previous studies in patients with NETs who received SSAs, suggesting that this domain may not be particularly sensitive in this patient population.22-24

The BM response rate of 20% in the placebo group was a somewhat unexpected observation in our study. Although the placebo effect is well documented in clinical trials,25,26 BM frequency is a relatively robust and objective end point and, in theory, should not be susceptible to subjective reporting. Use of short-acting rescue SSA therapy was somewhat more common in the placebo arm of this study and may have partially accounted for our observations. In addition, variability in the absorption of long-acting SSAs, differences in use of other antidiarrheal medications, and dietary changes may have contributed to the responses observed in the placebo group.

Treatment with telotristat ethyl significantly reduced u5-HIAA levels, suggesting effective TPH inhibition. u5-HIAA levels may vary for other reasons, and in prior studies of patients with NETs, ≥ 30% reduction in secretory biomarkers has been used as a measure of treatment efficacy to reduce the risk of capturing natural variability.27 In this study, > 78% of patients treated with telotristat ethyl (at either dosage) experienced a ≥ 30% decrease in u5-HIAA levels versus 10% in the placebo group. The broader clinical significance of decreasing systemic serotonin levels, as determined by u5-HIAA levels, in patients with carcinoid syndrome has not been fully established. However, serotonin stimulates fibroblast proliferation and has been linked to cardiac valvular fibrosis in patients with carcinoid syndrome.28 Serotonin may also mediate mesenteric fibrosis often observed in patients with small intestine NETs.29 Future studies examining whether these complications of carcinoid syndrome can be prevented by reducing serotonin production with telotristat ethyl are warranted.

Similar reductions in BM frequency were observed at both telotristat ethyl dosages; however, over time, numerically greater reductions in BM frequency were observed with telotristat ethyl.
500 mg from weeks 7 to 12. Reductions in u5-HIAA levels and in the EORTC QLQ-C30 diarrhea subscale, the proportion of days with the urgency to defecate, and improvements in stool consistency were also numerically greater with telotristat ethyl 500 mg. Telotristat ethyl 500 mg demonstrated a favorable long-term tolerability profile, suggesting that this dose may be beneficial to patients not adequately responding to initial treatment with telotristat ethyl 250 mg.

Telotristat ethyl was generally well tolerated in this patient population. Increases in transaminases and nausea were observed in previous studies of telotristat ethyl.\textsuperscript{11,12} In this study, these events did not result in treatment discontinuation in patients randomly assigned to receive telotristat ethyl. Telotristat ethyl did not appear to be associated with an increased incidence of serious TEAEs. Preclinical studies suggest that telotristat ethyl does not have significant CNS penetration.\textsuperscript{7} In this study, a higher incidence of depression-related events was observed in patients who received telotristat ethyl 500 mg than in patients who received placebo; however, incidences in patients who received telotristat ethyl 250 mg and placebo were nearly identical. Most events resolved on study, and no new antidepressant therapies were initiated. In the current interim analysis of the OLE, rates of depression-related events have been relatively low. However, these data may be subject to some degree of selection bias and should be interpreted with caution. Additional follow-up in the

### Table 3. TEAEs Reported in the DBT Period

<table>
<thead>
<tr>
<th>Category</th>
<th>Placebo (n = 45)</th>
<th>Telotristat Ethyl (three times per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAE</td>
<td>39 (86.7)</td>
<td>37 (82.2)</td>
</tr>
<tr>
<td>Study discontinuation as a result of TEAE*</td>
<td>6 (13.3)</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>TEAE resulting in death†</td>
<td>3 (6.7)</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td>Selected AEs occurring in ≥ 5% of patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>any study arm by system organ class</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and preferred term‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GI disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (11.1)</td>
<td>6 (13.3)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>8 (17.8)</td>
<td>5 (11.1)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4 (8.9)</td>
<td>2 (4.4)</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>3 (6.7)</td>
<td>2 (4.4)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3 (6.7)</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>3 (6.7)</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>4 (8.9)</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>1 (2.2)</td>
<td>2 (4.4)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AEs relating to investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased gamma-glutamyl transferase§</td>
<td>0</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Increased ALT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased alkaline phosphatase¶</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>2 (4.4)</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>3 (6.7)</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>2 (4.4)</td>
<td>5 (11.1)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2 (4.4)</td>
<td>0</td>
</tr>
<tr>
<td>Memory impairment</td>
<td>3 (6.7)</td>
<td>0</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression-related#</td>
<td>3 (6.7)</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Confusional state</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory, thoracic, and mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>0</td>
<td>2 (4.4)</td>
</tr>
<tr>
<td>Cough</td>
<td>1 (2.2)</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td>Vascular disorders (new or worsening)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flushing</td>
<td>2 (4.4)</td>
<td>3 (6.7)</td>
</tr>
</tbody>
</table>

NOTE: All data are presented as No. (%).

Abbreviations: AE, adverse event; DBT, double-blind treatment; TEAE, treatment-emergent adverse event.

*TEAEs leading to study discontinuation were anemia, cardiac arrest, nausea, vomiting, eructation, dyspepsia, chills, fatigue, general health deterioration, dehydation, disease progression (five patients), sepsis, rash, and increased gamma-glutamyl transferase.

†All deaths occurred in the setting of advanced metastatic disease.

‡AEs were graded according to a standard severity grading scheme as mild, moderate, or severe.

§Mean changes from baseline at week 12 in gamma-glutamyl transferase (U/L ± standard deviation [SD]) for all patients studied were 4.4 ± 31.6 in the placebo group, 130.0 ± 204.4 in the telotristat ethyl 250 mg three times per day group, and 242.4 ± 358.1 in the telotristat ethyl 500 mg three times per day group.

||Mean changes from baseline to week 12 in ALT (U/L ± SD) for all patients studied were –0.1 ± 6.2 in the placebo group, 7.1 ± 16.4 in the telotristat ethyl 250 mg three times per day group, and 17.4 ± 42.6 in the telotristat ethyl 500 mg three times per day group.

¶Mean changes from baseline to week 12 in alkaline phosphatase (U/L ± SD) for all patients studied were 16.1 ± 57.6 in the placebo group, 22.8 ± 41.8 in the telotristat ethyl 250 mg three times per day group, and 57.5 ± 140.8 in the telotristat ethyl 500 mg three times per day group.

#Depression-related AEs include depression, depressed mood, and decreased interest.
ongoing OLE and evaluation of safety data in a separate ongoing phase III study (clinical trial information: NCT02063659) are planned.

In conclusion, treatment with the oral TPH inhibitor telotristat ethyl (250 mg or 500 mg three times per day) was generally safe and well tolerated and was associated with a significant decrease in BM frequency in patients with carcinoid syndrome receiving treatment with SSAs. The associated decreases in u5-HIAA provide evidence that telotristat ethyl effectively decreases serotonin production and has the potential to mitigate serotonin-mediated complications in this patient population. These observations suggest that telotristat ethyl represents a potential new treatment approach for patients with carcinoid syndrome.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at ascopubs.org/journal/jco.

REFERENCES

2. Fox DJ, Khattar RS: Carcinoid heart disease: Presentation, diagnosis, and management. Heart 90: 1224-1228, 2004

AUTHOR CONTRIBUTIONS
 Provision of study materials or patients: Matthew H. Kulke, Dieter Hörsc, Martyn Caplin, Staffan Welin, Emily Bergslånd, Richard R.P. Warner, Catherine Lombard-Bohas, Pamela L. Kunz, Enrique Grande, Juan W. Valle, Marianne Pavel
 Collection and assembly of data: Dieter Hörsc, Martyn E. Caplin, Lowell B. Anthony, Kjell Öberg, Staffan Welin, Richard R.P. Warner, Catherine Lombard-Bohas, Pamela L. Kunz, Juan W. Valle, Douglas Fleming, Pablo Lapuerta, Shanna Jackson, Brian Zambrowicz, Marianne Pavel
 Data analysis and interpretation: Matthew H. Kulke, Dieter Hörsc, Martyn E. Caplin, Lowell B. Anthony, Emily Bergslånd, Kjell Öberg, Pamela L. Kunz, Enrique Grande, Juan W. Valle, Douglas Fleming, Pablo Lapuerta, Phillip Banks, Shanna Jackson, Brian Zambrowicz, Marianne Pavel
 Manuscript writing: All authors
 Final approval of manuscript: All authors
 Accountable for all aspects of the work: All authors
Affiliations

Matthew H. Kulke, Dana-Farber Cancer Institute, Boston; Douglas Fleming, Ipsen Bioscience, Cambridge, MA; Dieter Hörsch, Zentralklinik Bad Berka, Bad Berka; Marianne Pavel, Charité-Universitätsmedizin, Berlin, Germany; Martyn E. Caplin, Royal Free Hospital, London; Juan W. Valle, The University of Manchester-The Christie National Health Service Foundation Trust, Manchester, United Kingdom; Lowell B. Anthony, University of Kentucky, Lexington, KY; Emily Bergsland, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco; Pamela L. Kunz, Stanford University, Palo Alto, CA; Kjell Öberg and Staffan Welin, Uppsala University, Uppsala, Sweden; Richard R.P. Warner, Icahn School of Medicine at Mount Sinai, New York, NY; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Pablo Lapuerta, Phillip Banks, Shanna Jackson, Brian Zambrowicz, and Arthur T. Sands, Lexicon Pharmaceuticals, The Woodlands, TX; and Enrique Grande, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Support

Supported by Lexicon Pharmaceuticals.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Matthew H. Kulke
Consulting or Advisory Role: Novartis, Ipsen Biopharmaceuticals, Lexicon Pharmaceuticals

Dieter Hörsch
Honorary: Lexicon Pharmaceuticals, Ipsen Biopharmaceuticals, Novartis, Pfizer
Consulting or Advisory Role: Lexicon Pharmaceuticals, Ipsen Biopharmaceuticals, Pfizer, Novartis
Research Funding: Novartis
Travel, Accommodations, Expenses: Pfizer, Novartis, Ipsen Biopharmaceuticals

Pamela L. Kunz
Consulting or Advisory Role: Ipsen Biopharmaceuticals, Novartis, Lexicon Pharmaceuticals
Research Funding: Advanced Accelerator Applications (Inst), Genentech (Inst), Merck (Inst), Lexicon Pharmaceuticals (Inst), Novartis (Inst), OXiGENE (Inst), Esanex (Inst), Ipsen Biopharmaceuticals (Inst)

Catherine Lombard-Bohas
Consulting or Advisory Role: Novartis, Ipsen Biopharmaceuticals
Research Funding: Novartis

Enrique Grande
Consulting or Advisory Role: Lexicon Pharmaceuticals, Ipsen Biopharmaceuticals

J. W. Valle
Honoraria: Ipsen Biopharmaceuticals, Celgene, Novartis, AstraZeneca, Advanced Accelerator Applications, Sirtex Medical, Midatech Pharma, Eli Lilly, Merck, Baxalta
Consulting or Advisory Role: Ipsen Biopharmaceuticals, Sirtex Medical, Celgene, Novartis, AstraZeneca, Advanced Accelerator Applications, Eli Lilly, Merck, Baxalta
Speakers’ Bureau: Pfizer, Novartis, Abbott Nutrition, Celgene, Ipsen Biopharmaceuticals, Sirtex Medical
Research Funding: Novartis (Inst), AstraZeneca (Inst)
Travel, Accommodations, Expenses: Novartis, Celgene

Phillip Banks
Employment: Lexicon Pharmaceuticals
Stock or Other Ownership: Lexicon Pharmaceuticals, Merck
Travel, Accommodations, Expenses: Lexicon Pharmaceuticals

Spain Jackson
Employment: Lexicon Pharmaceuticals
Stock or Other Ownership: Lexicon Pharmaceuticals
Travel, Accommodations, Expenses: Lexicon Pharmaceuticals

Brian Zambrowicz
Employment: Lexicon Pharmaceuticals, Regeneron Pharmaceuticals
Leadership: Lexicon Pharmaceuticals, Regeneron Pharmaceuticals
Stock or Other Ownership: Lexicon Pharmaceuticals, Regeneron Pharmaceuticals
Consulting or Advisory Role: Lexicon Pharmaceuticals
Patents, Royalties, Other Intellectual Property: Lexicon: Inventor on pending US patents regarding methods and compounds for inhibiting tryptophan hydroxylase. Regeneron: Inventor on patent applications unrelated to this study.

Arthur T. Sands
Employment: Lexicon Pharmaceuticals, Nurix
Leadership: Lexicon Pharmaceuticals, Nurix
Stock or Other Ownership: Lexicon Pharmaceuticals, Nurix
Consulting or Advisory Role: Lexicon Pharmaceuticals

Marianne Pavel
Honoraria: Novartis, Ipsen Biopharmaceuticals, Pfizer, Lexicon Pharmaceuticals
Consulting or Advisory Role: Novartis, Ipsen Biopharmaceuticals, Pfizer, Lexicon Pharmaceuticals
Speakers’ Bureau: Novartis
Research Funding: Novartis, Ipsen Biopharmaceuticals

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Acknowledgment

Presented in part at the European Cancer Congress 2015, Vienna, Austria, September 25-29, 2015; North American Neuroendocrine Tumor Society Symposium Austin, Austin, TX, October 15-17, 2015; 12th Annual European Neuroendocrine Tumor Society (ENETS) Conference, Barcelona, Spain, March 11-13, 2015; and the 13th Annual ENETS Conference, Barcelona, Spain, March 9-11, 2016. We thank the patients and investigators for participating in the study and the Lexicon scientists who had the vision to develop a novel tryptophan hydroxylase inhibitor and successfully created telotristat ethyl. We thank Ammy Santiago, Chameleon Communications International (with funding provided by Lexicon Pharmaceuticals), for medical editorial assistance with this manuscript. We thank the following Lexicon employees: Linda Law for medical oversight during study initiation, Kenneth Kassler-Taub for oversight of clinical operations, Karie Arnold for clinical site management for the North American region, Ernest Wang for study monitoring, Rosanna Fleming for statistical analysis, Nam Wommack for data management, Heena Pandya and Wenjun Jiang for safety monitoring, and Kristi A. Boehm for her assistance with figure preparation, text formatting, and editing of this manuscript. We also thank the team at INC Research (Raleigh, NC) for study conduct, monitoring, analysis, and reporting.

Appendix

Fig A1. Mean daily use of rescue short-acting somatostatin analog (SSA) therapy in the double-blind treatment period. Some evidence that treatment with telotristat ethyl decreased the use of rescue short-acting SSA therapy was observed during the double-blind treatment period.
Table A1. Additional Secondary End Points of the DBT Period

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo (n = 45)</th>
<th>Telotristat Ethyl (three times per day)</th>
<th>Telotristat Ethyl (three times per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>P</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Flushing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline in daily flushing episodes averaged over 12 weeks, counts per day</td>
<td>–0.16 (1.16)</td>
<td>0.16</td>
<td>–0.30 (1.31)</td>
</tr>
<tr>
<td>Arithmetic mean treatment difference</td>
<td>–0.13</td>
<td>0.00</td>
<td>–0.26</td>
</tr>
<tr>
<td>Hodges-Lehmann estimator*</td>
<td>0.036</td>
<td>0.00</td>
<td>0.28</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline in abdominal pain averaged over 12 weeks, points†</td>
<td>–0.23 (1.16)</td>
<td>0.23</td>
<td>–0.49 (1.44)</td>
</tr>
<tr>
<td>Arithmetic mean treatment difference</td>
<td>–0.26</td>
<td>0.11</td>
<td>–0.11</td>
</tr>
<tr>
<td>Hodges-Lehmann estimator*</td>
<td>–0.17</td>
<td>0.17</td>
<td>0.28</td>
</tr>
<tr>
<td>Daily rescue short-acting SSA use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline in use of short-acting SSAs, averaged over 12 weeks, injections per day</td>
<td>0.18</td>
<td>0.18</td>
<td>–0.11</td>
</tr>
<tr>
<td>Arithmetic mean treatment difference</td>
<td>–0.30</td>
<td>0.15</td>
<td>–0.15</td>
</tr>
<tr>
<td>Hodges-Lehmann estimator*</td>
<td>0.09</td>
<td>0.09</td>
<td>0.19</td>
</tr>
<tr>
<td>Stool consistency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline in stool consistency averaged over 12 weeks, points</td>
<td>–0.22 (0.48)</td>
<td>0.22</td>
<td>–0.26 (0.47)</td>
</tr>
<tr>
<td>Arithmetic mean treatment difference</td>
<td>–0.09</td>
<td>0.15</td>
<td>–0.15</td>
</tr>
<tr>
<td>Hodges-Lehmann estimator*</td>
<td>–0.02</td>
<td>0.02</td>
<td>0.35</td>
</tr>
<tr>
<td>Urgency to defecate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proportion of days</td>
<td>0.75 (0.29)</td>
<td>0.75</td>
<td>0.67 (0.34)</td>
</tr>
<tr>
<td>Arithmetic mean treatment difference</td>
<td>–0.09</td>
<td>0.15</td>
<td>–0.15</td>
</tr>
</tbody>
</table>
| Abbreviations: DBT, double-blind treatment; SD, standard deviation; SSA, somatostatin analog. *Nonparametric measure derived as the median of all possible differences between the groups. †Abdominal pain based on patient rating using an 11-point scale: 0, no pain; 10, worst pain ever experienced.

Table A2. Quality-of-Life Outcomes During the DBT Period

<table>
<thead>
<tr>
<th>EORTC QLQ-C30 Subscale</th>
<th>Placebo (n = 45)</th>
<th>Telotristat Ethyl (three times per day)</th>
<th>Telotristat Ethyl (three times per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
<td>Mean (SD)</td>
<td>No. of Patients</td>
</tr>
<tr>
<td>Global health status/QoL*</td>
<td>39</td>
<td>–2.0 (18.3)</td>
<td>39</td>
</tr>
<tr>
<td>BM responders†</td>
<td>9</td>
<td>3.7 (30.4)</td>
<td>16</td>
</tr>
<tr>
<td>BM nonresponders†</td>
<td>25</td>
<td>–5.0 (18.0)</td>
<td>20</td>
</tr>
<tr>
<td>Diarrhea*</td>
<td>39</td>
<td>–8.5 (21.9)</td>
<td>39</td>
</tr>
<tr>
<td>BM responders†</td>
<td>9</td>
<td>–22.2 (33.3)</td>
<td>16</td>
</tr>
<tr>
<td>BM nonresponders†</td>
<td>25</td>
<td>–8.0 (27.7)</td>
<td>20</td>
</tr>
<tr>
<td>Nausea and vomiting‡</td>
<td>39</td>
<td>–2.4 (13.5)</td>
<td>39</td>
</tr>
<tr>
<td>Insomnia*</td>
<td>39</td>
<td>–7.7 (25.9)</td>
<td>40</td>
</tr>
<tr>
<td>Physical functioning*</td>
<td>39</td>
<td>–1.2 (13.3)</td>
<td>40</td>
</tr>
<tr>
<td>Role functioning*</td>
<td>39</td>
<td>–1.3 (16.8)</td>
<td>39</td>
</tr>
<tr>
<td>Emotional functioning*</td>
<td>39</td>
<td>0.5 (13.7)</td>
<td>39</td>
</tr>
<tr>
<td>Cognitive functioning*</td>
<td>39</td>
<td>0.0 (20.8)</td>
<td>39</td>
</tr>
<tr>
<td>Social functioning*</td>
<td>39</td>
<td>0.4 (15.8)</td>
<td>39</td>
</tr>
<tr>
<td>Fatigue‡</td>
<td>39</td>
<td>0.4 (18.7)</td>
<td>40</td>
</tr>
<tr>
<td>Pain†</td>
<td>39</td>
<td>1.7 (19.6)</td>
<td>40</td>
</tr>
<tr>
<td>Dyspnea*</td>
<td>39</td>
<td>1.7 (18.7)</td>
<td>40</td>
</tr>
<tr>
<td>Appetite loss‡</td>
<td>38</td>
<td>–7.5 (25.9)</td>
<td>40</td>
</tr>
<tr>
<td>Constipation†</td>
<td>38</td>
<td>0.9 (3.8)</td>
<td>39</td>
</tr>
<tr>
<td>Financial difficulties‡</td>
<td>38</td>
<td>–1.3 (19.1)</td>
<td>39</td>
</tr>
</tbody>
</table>

Abbreviations: BM, bowel movement; DBT, double-blind treatment; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; QoL, quality of life; SD, standard deviation.
*For all total/domain scores, a higher functional score indicates a more favorable outcome.
†Change from baseline at week 12 (points).
‡For all individual/symptom scores, a higher score indicates a less favorable patient outcome.

NOTE. EORTC QLQ-C30 subscales show mean change from baseline averaged over 12 weeks (points), unless otherwise specified.

© 2016 by American Society of Clinical Oncology
### Table A3. All AEs Occurring in ≥ 5% of Patients in Any Study Arm in the DBT Period

<table>
<thead>
<tr>
<th>AE (system organ class preferred term)</th>
<th>Placebo (n = 45)</th>
<th>Telotristat Ethyl (three times per day)</th>
<th>Total (N = 135)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>250 mg (n = 45)</td>
<td>500 mg (n = 45)</td>
<td></td>
</tr>
<tr>
<td><strong>GI disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (11.1)</td>
<td>6 (13.3)</td>
<td>14 (31.1)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>8 (17.8)</td>
<td>5 (11.1)</td>
<td>10 (22.2)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4 (8.9)</td>
<td>2 (4.4)</td>
<td>5 (11.1)</td>
</tr>
<tr>
<td>Upper abdominal pain</td>
<td>0</td>
<td>2 (4.4)</td>
<td>5 (11.1)</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>3 (6.7)</td>
<td>2 (4.4)</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td>Flatulence</td>
<td>1 (2.2)</td>
<td>3 (6.7)</td>
<td>2 (4.4)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>3 (6.7)</td>
<td>1 (2.2)</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>4 (8.9)</td>
<td>4 (8.9)</td>
<td>7 (15.6)</td>
</tr>
<tr>
<td>Asthenia</td>
<td>3 (6.7)</td>
<td>2 (4.4)</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>1 (2.2)</td>
<td>3 (6.7)</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>2 (4.4)</td>
<td>3 (6.7)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>1 (2.2)</td>
<td>2 (4.4)</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>0</td>
<td>0</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td><strong>AEs relating to investigations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased gamma-glutamyl transferase*</td>
<td>0</td>
<td>4 (8.9)</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Increased ALT†</td>
<td>0</td>
<td>1 (2.2)</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Increased alkaline phosphatase‡</td>
<td>0</td>
<td>0</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>2 (4.4)</td>
<td>3 (6.7)</td>
<td>7 (15.6)</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>3 (6.7)</td>
<td>3 (6.7)</td>
<td>5 (11.1)</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>2 (4.4)</td>
<td>5 (11.1)</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2 (4.4)</td>
<td>0</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Memory impairment</td>
<td>3 (6.7)</td>
<td>0</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression-related§</td>
<td>3 (6.7)</td>
<td>3 (6.7)</td>
<td>7 (15.6)</td>
</tr>
<tr>
<td>Confusional state</td>
<td>0</td>
<td>0</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic, and mediastinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>0</td>
<td>2 (4.4)</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Cough</td>
<td>1 (2.2)</td>
<td>1 (2.2)</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>0</td>
<td>0</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td><strong>Vascular disorders (new or worsening)</strong></td>
<td>2 (4.4)</td>
<td>3 (6.7)</td>
<td>3 (6.7)</td>
</tr>
</tbody>
</table>

NOTE. Adverse events (AEs) were graded according to a standard severity grading scheme as mild, moderate, or severe. All data are presented as No. (%). Abbreviation: DBT, double-blind treatment.

*Mean changes from baseline to week 12 in gamma-glutamyl transferase (U/L ± standard deviation [SD]) for all patients studied were 4.4 ± 31.6 in the placebo group, 130.0 ± 204.4 in the telotristat ethyl 250 mg three times per day group, and 242.4 ± 358.1 in the telotristat ethyl 500 mg three times per day group.

†Mean changes from baseline to week 12 in ALT (U/L ± SD) for all patients studied were –0.1 ± 6.2 in the placebo group, 7.1 ± 16.4 in the telotristat ethyl 250 mg three times per day group, and 17.4 ± 42.6 in the telotristat ethyl 500 mg three times per day group.

‡Mean changes from baseline to week 12 in alkaline phosphatase (U/L ± SD) for all patients studied were 16.1 ± 57.6 in the placebo group, 22.8 ± 41.8 in the telotristat ethyl 250 mg three times per day group, and 57.5 ± 140.8 in the telotristat ethyl 500 mg three times per day group.

§Depression-related AEs include depression, depressed mood, and decreased interest.
Table A4. Summary of TEAEs Reported During the OLE

<table>
<thead>
<tr>
<th>Category</th>
<th>OLE* (n = 115)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
</tr>
<tr>
<td>Any TEAE</td>
<td>105</td>
</tr>
<tr>
<td>Any serious TEAE†</td>
<td>36</td>
</tr>
<tr>
<td>Study discontinuation as a result of TEAE‡</td>
<td>14</td>
</tr>
<tr>
<td>TEAE resulting in death§</td>
<td>8</td>
</tr>
<tr>
<td>Selected key AEs</td>
<td></td>
</tr>
<tr>
<td>Any depression-related AE¶</td>
<td>17</td>
</tr>
<tr>
<td>Nausea</td>
<td>23</td>
</tr>
<tr>
<td>Increased gamma-glutamyl transferase</td>
<td>7</td>
</tr>
<tr>
<td>Increased alanine aminotransferase</td>
<td>4</td>
</tr>
<tr>
<td>Increased alkaline phosphatase</td>
<td>5</td>
</tr>
</tbody>
</table>

**Abbreviations:** AE, adverse event; OLE, open-label extension; TEAE, treatment-emergent adverse event.

*Patients were initiated at 500 mg telotristat ethyl three times per day. Mean treatment exposure was 11.3 weeks in the double-blind treatment period and 26.7 weeks in the OLE.

†AEs were considered serious if they involved death, a life-threatening AE, inpatient hospitalization, a persistent or significant incapacity, substantial disruption in the ability to conduct normal life function, or a congenital anomaly or birth defect.

‡TEAEs leading to study discontinuation in the OLE were supraventricular tachycardia, disease progression (five patients), abdominal distension, constipation, GI hemorrhage, hematemesis, large intestine perforation, asthenia, fatigue, general physical health deterioration, hepatomegaly, peritonitis, sepsis, increased liver enzymes, decreased weight, decreased appetite, dehydration, mental confusion, cognitive disorder, renal failure, and urticaria.

§None of the deaths occurring during the OLE were considered related to study drug. The deaths were generally attributable to the progression or complication of the underlying disease.

¶Depression-related AEs include depression, depressed mood, and decreased interest.